Drug Profile


Alternative Names: MDL 72974; MDL 72974A

Latest Information Update: 16 Jun 1996

Price : $50

At a glance

  • Originator Aventis
  • Class Allyl compounds; Antiparkinsonians; Nootropics; Small molecules
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 16 Jun 1996 Discontinued-III for Parkinson's disease in USA (PO)
  • 11 Jun 1996 A clinical study has been added to the pharmacodynamics and pharmacokinetics section
  • 06 Jun 1995 A clinical study has been added to the pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top